<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591210</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-3212</org_study_id>
    <nct_id>NCT04591210</nct_id>
  </id_info>
  <brief_title>The COVID-RASi Trial (COVID-19)</brief_title>
  <official_title>Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-RASi study is an international randomized clinical trial that will evaluate the&#xD;
      potential benefit of angiotensin modulators on clinical outcomes, in COVID-19 patients who&#xD;
      are at high-risk for cardiovascular disease. The purpose of this study is to determine if&#xD;
      renin-angiotensin system inhibitors (RASi), with angiotensin-converting enzyme inhibitors&#xD;
      (ACEi) or angiotensin II receptor blockers (ARB), has a beneficial effect in high-risk older&#xD;
      patients with COVID-19 infections, by reducing ICU admission, ventilator requirement or&#xD;
      death. We would also like to determine if there are differences between ACEi and ARB&#xD;
      therapeutic treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>28 days</time_frame>
    <description>Within first 28 days post randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Within first 28 days post randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU admission</measure>
    <time_frame>28 days</time_frame>
    <description>Within first 28 days post randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>28 days</time_frame>
    <description>Within first 28 days post randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospitalization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients require intensive care</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients requiring ventilation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients requiring dialysis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1155</enrollment>
  <condition>COVID-19</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>No Treatment (Standard of Care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEi treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The physician will initiate any ACE inhibitor and dose at their discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARB treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The physician will initiate any ARB and dose at their discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin converting enzyme inhibitor</intervention_name>
    <description>The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.</description>
    <arm_group_label>ACEi treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II Receptor Blockers</intervention_name>
    <description>The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.</description>
    <arm_group_label>ARB treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with COVID-19 diagnosis with laboratory confirmation within the last 30 days&#xD;
             AND&#xD;
&#xD;
          -  Age 65 years old or greater if outpatient OR age over 40 years old if inpatient&#xD;
             (admitted to the hospital) at time of recruitment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to ARB or ACEi, including severe aortic stenosis and angioedema&#xD;
&#xD;
          -  Patients who are currently on active treatment with ARB/ACEi&#xD;
&#xD;
          -  Known bilateral renal artery stenosis&#xD;
&#xD;
          -  Systolic BP â‰¤90 mmHg&#xD;
&#xD;
          -  eGFR&lt;30 ml/min, if not receiving dialysis treatment&#xD;
&#xD;
          -  K&gt;5.5 mmol/L on screening laboratory testing&#xD;
&#xD;
          -  Recent history of dizziness, vertigo, or orthostatic hypotension&#xD;
&#xD;
          -  Acute respiratory distress syndrome requiring invasive ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ermina Moga</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>10945</phone_ext>
    <email>EMoga@ottawaheart.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Pesquisa Clinicas Dr Marco Mota</name>
      <address>
        <city>Maceio</city>
        <state>Alagoas</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Mota Gomes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Itabuna</name>
      <address>
        <city>Itabuna</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Kowalski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Felicio Rocho</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Carolina Procopio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clinica da Unimed Campo Grande</name>
      <address>
        <city>Campo Grande</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delcio da Silva Jr, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de Campo Grande</name>
      <address>
        <city>Campo Grande</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Wanderley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Agamenom Magalhaes</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joao de Moraes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pronto Socorro Cardiologico de Pernambuco Recife</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audes Feitosa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Atena de Pesquisa Clinica</name>
      <address>
        <city>Natal</city>
        <state>RN</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Paiva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitar Canoas</name>
      <address>
        <city>Canoas</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristiano Jaeger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Tognon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Saraiva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Bela Vista</name>
      <address>
        <city>Consolacao</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo de Paula, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Prevent Senior</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Esper, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Coracao</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Lima, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Goiano de Oncologia e Hematologia</name>
      <address>
        <city>GoiÃ¢nia</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayler Olombrada Nunes de Santos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alberta Health Services</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Ezekowitz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General 1, IMSS</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Escobedo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de zona 27- IMSS</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelin Garcia, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>corona virus</keyword>
  <keyword>COVID-19</keyword>
  <keyword>severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)</keyword>
  <keyword>elderly</keyword>
  <keyword>senior</keyword>
  <keyword>Angiotensin-converting enzyme inhibitors</keyword>
  <keyword>ACEi</keyword>
  <keyword>Renin-angiotensin system inhibitors</keyword>
  <keyword>RASi</keyword>
  <keyword>Angiotensin receptor blockers</keyword>
  <keyword>ARB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Giapreza</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

